Rep. April McClain Delaney Purchases Shares of STERIS plc (NYSE:STE)

Key Points

• Representative April McClain Delaney of Maryland purchased between $1,001 and $15,000 in shares of STERIS plc (NYSE:STE) on September 11th, as disclosed in a filing on October 6th.
• STERIS has reported a quarterly EPS of $2.34, exceeding analyst expectations and a revenue increase of 8.8% year-over-year, signaling positive financial health.
• The company recently raised its quarterly dividend from $0.57 to $0.63 per share, reflecting a 1.0% yield and a payout ratio of 38.59%.

Representative April McClain Delaney (D-Maryland) recently bought shares of STERIS plc NYSE: STE. In a filing disclosed on October 06th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on September 11th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Nasdaq NASDAQ: NDAQ on 9/19/2025.
• Sold $1,001 - $15,000 in shares of Silicon Graphics International NASDAQ: SGI on 9/19/2025.
• Purchased $1,001 - $15,000 in shares of STERIS NYSE: STE on 9/18/2025.
• Sold $1,001 - $15,000 in shares of Middleby NASDAQ: MIDD on 9/18/2025.
• Purchased $1,001 - $15,000 in shares of Brown & Brown NYSE: BRO on 9/18/2025.
• Purchased $1,001 - $15,000 in shares of Jones Lang LaSalle NYSE: JLL on 9/18/2025.
• Sold $1,001 - $15,000 in shares of Dayforce NYSE: DAY on 9/11/2025.
• Purchased $1,001 - $15,000 in shares of BJ's Wholesale Club NYSE: BJ on 8/25/2025.
• Purchased $15,001 - $50,000 in shares of Markel Group NYSE: MKL on 8/21/2025.
• Sold $15,001 - $50,000 in shares of Dayforce NYSE: DAY on 8/19/2025.

STERIS Price Performance

STERIS stock opened at $241.58 on Wednesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The firm has a market cap of $23.79 billion, a P/E ratio of 37.00 and a beta of 1.01. The business's fifty day moving average is $243.63 and its two-hundred day moving average is $235.54. STERIS plc has a 52 week low of $200.98 and a 52 week high of $253.00.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.32 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.The business's revenue was up 8.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.03 earnings per share. Equities research analysts forecast that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 26th. Shareholders of record on Thursday, September 4th were paid a $0.63 dividend. This is an increase from STERIS's previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, September 4th. STERIS's payout ratio is presently 38.59%.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Spurstone Advisory Services LLC bought a new stake in STERIS in the second quarter valued at about $29,000. Geneos Wealth Management Inc. increased its holdings in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Grove Bank & Trust increased its holdings in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 142 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in STERIS in the first quarter valued at about $37,000. Finally, ORG Wealth Partners LLC bought a new stake in STERIS in the first quarter valued at about $43,000. Institutional investors own 94.69% of the company's stock.

Analyst Ratings Changes

STE has been the subject of a number of recent research reports. Wall Street Zen upgraded STERIS from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 14th. Morgan Stanley boosted their target price on STERIS from $276.00 to $295.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Weiss Ratings restated a "buy (b-)" rating on shares of STERIS in a research report on Saturday, September 27th. Finally, KeyCorp boosted their target price on STERIS from $277.00 to $288.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 22nd. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $273.50.

Insider Buying and Selling

In related news, CAO Karen L. Burton sold 7,900 shares of the company's stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.73, for a total value of $1,909,667.00. Following the completion of the sale, the chief accounting officer owned 5,994 shares in the company, valued at approximately $1,448,929.62. This represents a 56.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Cynthia L. Feldmann sold 3,495 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $241.56, for a total value of $844,252.20. Following the completion of the sale, the director owned 705 shares of the company's stock, valued at $170,299.80. This trade represents a 83.21% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,709 shares of company stock worth $4,546,940. Company insiders own 1.07% of the company's stock.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland's 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland's 6th Congressional District. She declared candidacy for the 2026 election. April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor's degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.